Dana-Farber Cancer Institute is running a clinical trial to test drugs called Ibrutinib, Fludarabine, Cyclophosphamide and Rituximab to treat chronic lymphocytic leukemia. This research study is evaluating a new drug called ibrutinib in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic Lymphocytic Leukemia (CLL).
The drugs are Ibrutinib, Fludarabine, Cyclophosphamide and Rituximab.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 85 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia |
| Actual Study Start Date : | October 2014 |
| Estimated Primary Completion Date : | April 2018 |
| Estimated Study Completion Date : | April 2021 |
For enrollment please visit www.clinicaltrials.gov.
